Slide 1: Exchange filing cover letter
Ia 6th November, 2019 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Sandra Kurla Complex, Sandra (East), Mumbai - 400 051 Scrip Code: 500087
Slide 2: Investor Presentation Q2FY20
Investor Presentation Q2FY20 06-11-2019
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Key highlights
Key highlights: Overall India Rx India Gx South Africa 1 Continued growth across key markets 10% 13% 61% 13% (Q2 YoY Growth) (Q2 YoY Growth) (QoQ Growth) (Private Market Q2 YoY Growth; ZAR ) 2 Strong EBITDA margin ~21% 21% trajectory (Q2 EBITDA) Q2 EBITDA YoY Growth Retained share in Cinacalcet 3 Mo
Slide 5: Financial Performance – Q2FY20
Financial Performance – Q2FY20 Revenues INR 4,396 Cr 10% EBITDA INR 909 Cr ~21% to sales 21% Q2 FY20 (Consolidated) Revenue1 Break-up Actuals Global API, Others, vs Q2 FY 19 (Rs Cr) 4% 4% Total Revenue from Europe, 4% 4,396 10% Operations a) Domestic Sales 1,810 9% Emerging India, 40% Mkts, 10% b) I
Slide 6: Continued focus on maintaining balance sheet health with strong cash flow generation
Continued focus on maintaining balance sheet health with strong cash flow generation Gross Debt Net Debt / Equity 4,316 0.10 3,557 0.08 Mar'19 Sept'19 Mar'19 Sept'19 Loan repayment of US$110mn made during the quarter, a year ahead of schedule Reduction in Net Debt/Equity despite continued growth
Slide 7: India (Rx + Gx): Strong recovery in generics and momentum in branded business
India (Rx + Gx) : Strong recovery in the generics business and momentum across key therapies in the branded business Q2 Y-o-Y Q2 Q-o-Q Rs Cr Rs Cr 2000 2000 1745 1745 1800 1800 1644 29% 6% 1600 1355 1600 1400 1400 1200 1200 1000 1000 800 800 600 600 400 400 200 200 0 0 Q2 FY 19 Q2 FY 20 Q1 FY20 Q2 F
Slide 8: North America: Momentum continues behind new launches and retained share
North America: Momentum continues behind new launches and retained share on key assets Key Business Highlights Q1 Y-o-Y • Continue to retain share in Cinacalcet despite multiple competitors launching the product; contribution in value terms substantially normalized $ Mn • Launch of Pregabalin and Da
Slide 9: ANDA Portfolio & Pipeline (As on 30th Sept 2019)
ANDA1 Portfolio & Pipeline (As on 30th Sept 2019) Total 172 22 63 257 ANDAs ANDA Portfolio 31 56 9 4 23 76 2 3 1 34 11 7 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs Cipla Ltd Cipla-PEPFAR2 Invagen Partnered ANDAs 1 Does not include Vet product ANDAs 2 PEPFAR approved ANDAs can be
Slide 10: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access Q2 Y-o-Y Q2 Q-o-Q $ Mn $ Mn SA Private Market 13% YoY 36 28 23 28 ZAR Terms 21 30 21 20 9% 18% South Africa Private South Africa 52 56 48 56 Tender Others (SSA & CGA) Q2 FY19 Q2 FY20 Q1 FY20 Q2 FY20 Key Business Highlights South Africa:
Slide 11: EM, Europe and API
EM, Europe and API Emerging Markets Europe API $ Mn $ Mn $ Mn 30 30 80 27 24 67 25 33% 25 22 70 64 -9% -5% 20 60 20 20 50 15 15 40 30 10 10 20 5 5 10 0 0 0 Q2 FY19 Q2 FY20 Q2 FY19 Q2 FY20 Q2 FY19 Q2 FY20 Strengthening portfolio offering in key markets: Growth driven by performance in key Key cus
Slide 12: Key priorities for the upcoming quarters
Key priorities for the upcoming quarters: India Leverage on the momentum and continue to drive performance across both branded and 1 o generics o Launch Berok 2.0: Second version of Cipla’s flagship patient-focused initiatives in Respiratory South Africa 2 o Continue growth momentum in the private m
Slide 13: Thank you
Thank you Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com Investor Presentation: Q2FY20 12